Acute Lung Injury Market to Grow at a CAGR of 4.7% to reach US$ 741.98 million from 2021 to 2028

Acute Lung Injury Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapy (Mechanical Ventilation, Fluid Management, Pharmacotherapy, and Adjunctive Procedures) and End User (Hospitals, Ambulatory Surgery Centers, and Others) and Geography

  • Report Code : TIPRE00015798
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 141
Buy Now

Acute Lung Injury Market to Grow at a CAGR of 4.7% to reach US$ 741.98 million from 2021 to 2028

Buy Now

The acute lung injury market is projected to reach US$ 741.98 million by 2028 from US$ 539.61 million in 2021; it is expected to register a CAGR of 4.7% from 2021 to 2028.

Acute lung injury (ALI) is a life-threatening condition in critically unhealthy patients. In acute lung injury disorder, acute inflammation occurs in the lung, which leads to the disruption of the lung endothelial and epithelial barriers. The alveolar-capillary membrane is composed of the microvascular endothelium, interstitium, and alveolar epithelium. Acute Lung Injury Market is diagnosed clinically based on the appearance of non-cardiogenic pulmonary odema and respiratory failure in a critically ill patient. Its incidence is normal; it is likely to exist outside the intensive care setting and therefore is a condition relevant to all clinicians.

The report offers insights and in-depth analysis of the acute lung injury market, emphasizing various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players worldwide. It also includes the impact of the COVID-19 pandemic on the market across all the regions. The COVID-19 pandemic has disrupted the socioeconomic conditions of various countries across the world. Presently, the US is the world's worst-affected country due to the COVID-19 outbreak with the highest number of confirmed cases and deaths, as per the recent WHO statistics. The high number of COVID cases has negatively impacted the country's and region's economies. There has been a decline in overall business activities and growth of various industries operating in the region.

However, acute lung injury market players are initiating clinical trials to develop drugs to treat acute lung injury. For instance, Chimerix, a biopharmaceutical company, initiated a Phase II/III clinical trial in June 2020 to evaluate the safety and efficacy of Dociparstat sodium (DSTAT) in patients with acute lung injury (ALI) due to COVID-19. Furthermore, Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for acute lung injury (ALI) as a result of viral infections such as COVID-19, respiratory syncytial virus (RSV), and influenza. COVID-19-related issues have propelled the acute lung injury market growth in the region.

Based on region, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Acute Lung Injury Market: Strategic Insights

acute-lung-injury-market
Market Size Value inUS$ 539.61 million in 2021
Market Size Value byUS$ 741.98 million by 2028
Growth rateCAGR of 4.7% from 2021-2028
Forecast Period2021-2028
Base Year2021
Analyst Image

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Market Insights

Increasing Prevalence of Respiratory Diseases Drives Acute Lung Injury Market

The high prevalence of respiratory conditions is associated with the decrease in the size of the upper airway lumen in the aging population. Lung disorders are among the most common medical conditions across the world. According to the Centers for Disease Control and Prevention (CDC), lung diseases such as chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI) are the third leading cause of death in the US. People worldwide suffer from various sorts of respiratory diseases. Smoking, infections, and genetic factors are among the common factors responsible for respiratory disorders. Medical conditions such as COPD, asthma, chronic bronchitis, cystic fibrosis, and lung cancer are significant public health burdens.

Patients suffering from these respiratory disorders commonly experience difficulty in breathing. The respiratory failure associated with acute lung injury or the acute respiratory distress syndrome (ARDS) is one of the most critical contributors to postoperative mortality.

Moreover, the CDC, the US Food and Drug Administration (FDA), state and local health departments, and other clinical and public health associates continue to monitor smoking e-cigarette or vaping product use associated lung injury (EVALI). According to the CDC, a total of 2,807 hospitalized EVALI cases or deaths from all 50 states, the District of Columbia, and two US territories (Puerto Rico and US Virgin Islands) have been recorded as of February 2020. Thus, all the factors mentioned above are expected to result in the growth of the acute lung injury market during the forecast period.

Therapy-Based Insights

Based on therapy, the acute lung injury market is segmented into mechanical ventilation, fluid management, pharmacotherapy, and adjunctive procedures. In 2021, the mechanical ventilation segment accounted for the largest market share in the global acute lung injury market. The segment's growth is attributed to the fact that mechanical ventilation in acute lung injury (ALI) aims to maintain oxygen while avoiding its toxicity and complications associated with the ventilation.

End User-Based Insights

Based on end user, the acute lung injury market is segmented into hospitals, ambulatory surgery centers, and others. The hospitals segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR of 4.9% of the market during the forecast period.

The acute lung injury market players adopt organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide and meet the growing demand.

Acute Lung Injury Market Report Scope

By Therapy

  • Mechanical Ventilation
  • Fluid Management
  • Pharmacotherapy
  • Adjunctive Procedures

By End User

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

By

Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of SCAM


Company Profiles

  • GlaxoSmithKline plc.
  • Stemedica Cell Technologies, Inc
  • Histocell
  • APEPTICO Forschung und Entwicklung GmbH
  • Windtree Therapeutics, Inc.
  • ReAlta Life Sciences, Inc.
  • Apeiron Biologics AG
  • Qx Therapeutics, Inc.
  • Angion
  • Asklepion Pharmaceuticals, LLC                                                         
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Therapy and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


Who are the key players in the acute lung injury market?

The acute lung injury market majorly consists of players like GlaxoSmithKline plc., Stemedica Cell Technologies, Inc, Histocell, APEPTICO Forschung und Entwicklung GmbH, Windtree Therapeutics, Inc., ReAlta Life Sciences, Inc., Apeiron Biologics AG, Qx Therapeutics, Inc., Angion, and Asklepion Pharmaceuticals, LLC. among others. Histocell and APEPTICO Forschung und Entwicklung GmbH are the top most two companies in the market.

What are the drivers and restraints for the acute lung injury market?

The growth of the market is attributed to increasing prevalence of respiratory diseases, and rising geriatric population drive the market growth. However, high cost of therapies hampers the market growth.

Which is the potential market for the acute lung injury in terms of region?

Asia Pacific is expected to be the fastest growing region and potential market for acute lung injury. Asia Pacific is expected to expand at a high growth rate. The growth of the acute lung injury market in this region is primarily due to high prevalence of this disease, and the rise in healthcare awareness related to the disease diagnosis. Additionally, developing healthcare infrastructure and increasing investments to boost the manufacturing capacities are projected to drive the Asia Pacific acute lung injury market during the forecast period.

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Acute Lung Injury Market – By Therapy

1.3.2 Global Acute Lung Injury Market – By End User

1.3.3 Global Acute Lung Injury Market– By Geography

2. Global Acute Lung Injury Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Acute Lung Injury Market– Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America – PEST Analysis

4.2.2 Europe– PEST Analysis

4.2.3 Asia Pacific – PEST Analysis

4.2.4 Middle East and Africa – PEST Analysis

4.2.5 South and Central America (SCAM) – PEST Analysis

4.3 Experts Opinion

5. Acute Lung Injury Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Respiratory Diseases

5.1.1 Rising Geriatric Population

5.2 Market Restraints

5.2.1 High Cost of Therapies

5.3 Market Opportunities

5.3.1 Technological Advancements by Market Players

5.4 Future Trends

5.4.1 Growing Pipeline Drugs

5.5 Impact Analysis

6. Acute Lung Injury Market– Global Analysis

6.1 Global Acute Lung Injury Market Revenue Forecast and Analysis

6.2 Global Acute Lung Injury Market, By Geography - Forecast and Analysis

6.3 Market Positioning of Key Players

7. Acute Lung Injury Market Analysis and Forecast to 2028 – By Therapy

7.1 Overview

7.2 Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)

7.3 Mechanical Ventilation

7.3.1 Overview

7.3.2 Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Fluid Management

7.4.1 Overview

7.4.2 Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Pharmacotherapy

7.5.1 Overview

7.5.2 Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Adjunctive Procedures

7.6.1 Overview

7.6.2 Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

8. Acute Lung Injury Market Analysis – By End-User

8.1 Overview

8.2 Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)

8.3 Hospitals

8.3.1 Overview

8.3.2 Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Ambulatory Surgery Centers

8.4.1 Overview

8.4.2 Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Others

8.5.1 Overview

8.5.2 Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

9. Global Acute Lung Injury Market – Geographic Analysis

9.1 North America: Acute Lung Injury Market

9.1.1 Overview

9.1.2 North America: Acute Lung Injury Market - Revenue and Forecast to 2028 (USD Million)

9.1.3 North America Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.4 North America Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)

9.1.5 North America: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

9.1.5.1 US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.5.1.1 US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.5.1.2 US Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.5.1.3 US Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)

9.1.5.2 Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.5.2.1 Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.5.2.2 Canada Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.5.2.3 Canada Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)

9.1.5.3 Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.5.3.1 Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.5.3.2 Mexico Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.5.3.3 Mexico Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)

9.2 Europe: Acute Lung Injury Market

9.2.1 Overview

9.2.2 Europe: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.3 Europe: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.2.4 Europe: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.2.5 Europe: Acute Lung Injury Market, by Country, 2021 & 2028(%)

9.2.5.1 Germany: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.1.1 Germany: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.1.2 Germany: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.2.5.1.3 Germany: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.2.5.2 France: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.2.1 France: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.2.2 France: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.2.5.2.3 France: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.2.5.3 UK: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.3.1 UK: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.3.2 UK: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.2.5.3.3 UK: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.2.5.4 Italy: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.4.1 Italy: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.4.2 Italy: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.2.5.4.3 Italy: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.2.5.5 Spain: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.5.1 Spain: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.5.2 Spain: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.2.5.5.3 Spain: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.2.5.6 Rest of Europe: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.6.1 Rest of Europe: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.2.5.6.2 Rest of Europe: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.2.5.6.3 Rest of Europe: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.3 Asia Pacific: Acute Lung Injury Market

9.3.1 Overview

9.3.2 Asia Pacific: Acute Lung Injury Market - Revenue and Forecast to 2028 (USD Million)

9.3.3 Asia Pacific: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.3.4 Asia Pacific: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.3.5 Asia Pacific: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

9.3.5.1 China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.1.1 China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.1.2 China: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.3.5.1.3 China: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.3.5.2 Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.2.1 Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.2.2 Japan: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.3.5.2.3 Japan: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.3.5.3 India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.3.1 India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.3.2 India: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.3.5.3.3 India: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.3.5.4 South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.4.1 South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.4.2 South Korea: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.3.5.4.3 South Korea: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.3.5.5 Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.5.1 Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.5.2 Australia: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.3.5.5.3 Australia: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.3.5.6 Rest of Asia Pacific: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.6.1 Rest of Asia Pacific: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.3.5.6.2 Rest of Asia Pacific: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.3.5.6.3 Rest of Asia Pacific: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.4 Middle East and Africa: Acute Lung Injury Market

9.4.1 Overview

9.4.2 Middle East and Africa: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.3 Middle East and Africa: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.4.4 Middle East and Africa: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.4.5 Middle East and Africa: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

9.4.5.1 Saudi Arabia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.5.1.1 Saudi Arabia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.5.1.2 Saudi Arabia: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.4.5.1.3 Saudi Arabia: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.4.5.2 South Africa: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.5.2.1 South Africa: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.5.2.2 South Africa: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.4.5.2.3 South Africa: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.4.5.3 UAE: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.5.3.1 UAE: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.5.3.2 UAE: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.4.5.3.3 UAE: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.4.5.4 Rest of Middle East and Africa: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.5.4.1 Rest of Middle East and Africa: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.4.5.4.2 Rest of Middle East and Africa: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.4.5.4.3 Rest of Middle East and Africa: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.5 South and Central America: Acute Lung Injury Market

9.5.1 Overview

9.5.2 South and Central America: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.5.3 South and Central America: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.5.4 South and Central America: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.5.5 South and Central America: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

9.5.5.1 Brazil: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.1.1 Brazil: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.1.2 Brazil: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.5.5.1.3 Brazil: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.5.5.2 Argentina: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.2.1 Argentina: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.2.2 Argentina: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.5.5.2.3 Argentina: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.5.5.3 Rest of South and Central America: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.3.1 Rest of South and Central America: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.5.5.3.2 Rest of South and Central America: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)

9.5.5.3.3 Rest of South and Central America: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

10. Impact Of COVID-19 Pandemic on Acute Lung Injury Market

10.1 North America: Impact Assessment of COVID-19 Pandemic

10.2 Europe: Impact Assessment of COVID-19 Pandemic

10.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic

10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

11. Acute Lung Injury Market– Industry Landscape

11.1 Overview

11.2 Growth Strategies Done by the Companies in the Acute Lung Injury Market, (%)

11.3 Organic Developments

11.3.1 Overview

11.4 Inorganic Developments

11.4.1 Overview

12. Company Profiles

12.1 GlaxoSmithKline Plc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Stemedica Cell Technologies, Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Histocell

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 APEPTICO Forschung und Entwicklung GmbH

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Windtree Therapeutics, Inc.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 ReAlta Life Sciences, Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Apeiron Biologics AG

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Qx Therapeutics, Inc.

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Angion

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

12.10 Asklepion Pharmaceuticals, LLC.

12.10.1 Key Facts

12.10.2 Business Description

12.10.3 Products and Services

12.10.4 Financial Overview

12.10.5 SWOT Analysis

12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 2. North America Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 3. US Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 4. US Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 5. Canada Acute Lung Injury Market, by Therapy -Revenue and Forecast to 2028 (USD Million)

Table 6. Canada Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 7. Mexico Acute Lung Injury Market, by Therapy -Revenue and Forecast to 2028 (USD Million)

Table 8. Mexico Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 9. Europe: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 10. Europe: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 11. Germany: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 12. Germany: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 13. France: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 14. France: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 15. UK: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 16. UK: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 17. Italy: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 18. Italy: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 19. Spain: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 20. Spain: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 21. Rest of Europe: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 22. Rest of Europe: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 23. Asia Pacific: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 24. Asia Pacific: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 25. China: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)

Table 26. China: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 27. Japan: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)

Table 28. Japan: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 29. India: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)

Table 30. India: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 31. South Korea: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 32. South Korea: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 33. Australia: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 34. Australia: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 35. Rest of Asia Pacific: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 36. Rest of Asia Pacific: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 37. Middle East and Africa: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 38. Middle East and Africa: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 39. Saudi Arabia: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 40. Saudi Arabia: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 41. South Africa: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 42. South Africa: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 43. UAE: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 44. UAE: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 45. Rest of Middle East and Africa: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 46. Rest of Middle East and Africa: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 47. South and Central America: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 48. South and Central America: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 49. Brazil: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 50. Brazil: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 51. Argentina: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 52. Argentina: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 53. Rest of South and Central America: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 54. Rest of South and Central America: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 55. Organic Developments Done by Companies

Table 56. Inorganic Developments Done by Companies

Table 57. Glossary of Terms, Acute Lung Injury Market

LIST OF FIGURES

Figure 1. Acute Lung Injury Market Segmentation

Figure 2. Acute Lung Injury Market Segmentation, By Region

Figure 3. Global Acute Lung Injury Market Overview

Figure 4. Mechanical Ventilation Segment Held the Largest Share by Therapy in Acute Lung Injury Market

Figure 5. Asia Pacific to Show Significant Growth During Forecast Period

Figure 6. Acute Lung Injury Market, by Geography (US$ Million)

Figure 7. Global Acute Lung Injury Market– Leading Country Markets (US$ Million)

Figure 8. North America PEST Analysis

Figure 9. Europe and PEST Analysis

Figure 10. Asia Pacific PEST Analysis

Figure 11. Middle East and Africa PEST Analysis

Figure 12. South and Central America (SCAM) PEST Analysis

Figure 13. Acute Lung Injury Market Impact Analysis of Driver and Restraints

Figure 14. Global Acute Lung Injury Market– Revenue Forecast and Analysis – 2020- 2028

Figure 15. Global Acute Lung Injury Market – By Geography Forecast and Analysis – 2021- 2028

Figure 16. Market Positioning of Key Players in Global Acute Lung Injury Market

Figure 17. Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)

Figure 18. Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19. Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20. Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21. Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22. Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)

Figure 23. Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24. Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25. Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. North America: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)

Figure 27. North America Acute Lung Injury Market Revenue and Forecast to 2028 (USD Million)

Figure 28. North America: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

Figure 29. US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 30. Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 31. Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 32. Europe: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)

Figure 33. Europe: Acute Lung Injury Market Revenue and Forecast to 2028 (USD Million)

Figure 34. Europe: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

Figure 35. Germany: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 36. France: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 37. UK: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 38. Italy: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 39. Spain: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 40. Rest of Europe: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 41. Asia Pacific: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)

Figure 42. Asia Pacific: Acute Lung Injury Market Revenue and Forecast to 2028 (USD Million)

Figure 43. Asia Pacific: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

Figure 44. China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 45. Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 46. India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 47. South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 48. Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 49. Rest of Asia Pacific: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 50. Middle East and Africa: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)

Figure 51. Middle East and Africa: Acute Lung Injury Market Revenue and Forecast to 2028 (USD Million)

Figure 52. Middle East and Africa: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

Figure 53. Saudi Arabia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 54. South Africa: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 55. UAE: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 56. Rest of Middle East and Africa: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 57. South and Central America: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)

Figure 58. South and Central America: Acute Lung Injury Market Revenue and Forecast to 2028 (USD Million)

Figure 59. South and Central America: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

Figure 60. Brazil: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 61. Argentina: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 62. Rest of South and Central America: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 63. Impact of COVID-19 Pandemic in North American Country Markets

Figure 64. Impact of COVID-19 Pandemic in European Country Markets

Figure 65. Impact of COVID-19 Pandemic on Asia Pacific Country Markets

Figure 66. Impact of COVID-19 Pandemic in Middle East and Africa Country Markets

Figure 67. Impact Of COVID-19 Pandemic in South and Central America Africa Country Markets

Figure 68. Growth Strategies Done by the Companies in the Acute Lung Injury Market, (%)

The List of Companies - Acute Lung Injury Market

  1. GlaxoSmithKline plc.
  2. Stemedica Cell Technologies, Inc
  3. Histocell
  4. APEPTICO Forschung und Entwicklung GmbH
  5. Windtree Therapeutics, Inc.
  6. ReAlta Life Sciences, Inc.
  7. Apeiron Biologics AG
  8. Qx Therapeutics, Inc.
  9. Angion
  10. Asklepion Pharmaceuticals, LLC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Life Sciences : READ MORE..